Fees and Budget Planning for Belarus Medical Device Registration

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

The cost of registering a medical device in Belarus should be budgeted in three blocks: the state fee, the expert institution service fees, and third-party costs. Only the state fee has a clear legal basis — Article 287 of the Tax Code (Special Part) — but its specific amount could not be obtained from official texts by GRZAN, so this series marks fee figures throughout as a practical estimate. This matters for how the budget is defended internally: the three blocks differ not only in size but in predictability, and a budget that treats them as one lump sum will be contested precisely when the volatile block starts moving. The state fee is fixed by law but unverified in amount; the institution service fees follow the closed list of preliminary technical work and are therefore forecastable; the third-party block — translation, testing, logistics, the local representative — is where overruns concentrate. A budget document that separates the blocks, labels the certainty of each, and commits the fee line as pending confirmation until the authority communicates the actual figure will survive scrutiny far better than a single number carried forward from an earlier project.

2. Legal basis

RegulationNumber / referencePublication / effective dateProvision
Tax Code (Special Part)—currentArticle 287 (state fee; specific amount not obtained from official texts)
Preliminary Technical Work Prior to State RegistrationMinistry of Health No. 55 (as amended by No. 120)2015-04-23Regulatory basis for the items subject to service charging
State Registration (Re-registration) of Medical DevicesCouncil of Ministers No. 211 (6-1/55925)effective 2026-05-01Scope of preliminary technical work items (determines the scale of service fees)
Institution website service list—current pageNames of service items (prices to be checked against the price list)

The table separates the sources by what each can and cannot answer. Article 287 of the Tax Code establishes that a state fee exists and is legally owed, but without the official text its amount cannot be quoted. Ministry of Health Resolution No. 55 and Council of Ministers Resolution No. 211 together determine which work items make up the pre-registration stage, and therefore how many charged services the project will encounter. The institution’s own service list names the services, while actual prices live in the price list, which must be checked at quotation time rather than assumed from a past project.

3. Expert insights

Insight one: the three cost blocks differ completely in predictability. The state fee is set by law and is comparatively fixed; the institution service fees depend on the number of preliminary technical work items — and the closed list principle of No. 211 is exactly what makes that block forecastable; the third-party costs (translation, testing, logistics, the local representative) fluctuate the most and are the principal source of budget overruns. A finance owner who understands which block moves and which does not can run the project with targeted contingency instead of blanket padding, and can escalate deviations block by block rather than renegotiating the whole budget when one line item drifts.

Insight two: the closed list principle has direct value for budget management. Since the implementing organisation may not expand the list of preliminary technical work, a company can enumerate the payable service items with reasonable confidence before the project starts. This is the most commercially useful consequence of No. 211: it converts budgeting from add-as-you-go into estimable-before-start. The practical method is to walk the No. 55 list, mark each item as required, conditional or not applicable for the specific device class, and price the required items individually with the institution’s current price list.

Insight three: publicly circulated specific amounts should not be taken at face value. Figures quoted through different channels diverge widely, and GRZAN has not obtained an official text against which to verify them. When quoting externally, companies should treat the amounts as pending confirmation by the competent authority or the implementing organisation, and should write a possible fluctuation range into the contract terms. A tender or internal approval that locks an unverified fee number creates a compliance exposure of its own: the number can neither be defended from a legal source nor adjusted without reopening the approval.

Insight four: samples and testing are the bulk of third-party costs. Preparation and shipment of samples, together with laboratory fees for technical testing and biological testing, typically exceed the sum of the state fee and the institution service fees. Budgeting attention should therefore not concentrate on the fee line alone. The samples block deserves its own estimation, its own approval threshold and its own tracking, because it combines physical logistics with laboratory scheduling and is the block most exposed to exchange rate and freight movements during the project.

4. Practical recommendations

The recommendations below structure the budget so that each block can be managed on its own terms.

  1. Build the budget in three blocks. List the state fee, the institution service fees and the third-party costs separately, and label each with its certainty level so that finance readers can see which numbers are legal, quoted or estimated.
  2. Estimate institution service fees from the closed list. Enumerate the expected work items according to the No. 55 list and obtain a price for each item rather than negotiating one bundled figure.
  3. Treat the fee amount as to be confirmed. Agree in the contract that the state fee follows the actual communication of the competent authority, and do not lock a specific number that no official text currently supports.
  4. Single out samples and testing as key controlled items. Give these two items separate approval and tracking mechanisms, since they carry the largest amounts and the widest variation within the third-party block.

5. Verification checklist

  • □ The budget has been built in three blocks: state fee, institution service fees, third-party costs
  • □ Institution service fees have been priced item by item against the No. 55 list
  • □ The state fee amount has been marked as to be confirmed, with the contract providing for the actual notice to govern
  • □ Sample and testing costs have been listed separately with a tracking mechanism
  • □ External quotations do not use unverified specific amounts directly

Regulatory information verified as of 30 October 2026.

In the Eurasian Economic Union market, GRZAN concentrates its core capabilities on three areas. First, distinguishing between the applicability conditions and the remaining time windows of the two channels, the Union-wide registration and the national registration of each member state — the national registration procedure of Belarus has been fully re-routed by the Council of Ministers Resolution No. 211 of 28 April 2026 (state register number 6-1/55925, effective 2026-05-01), which compresses the total timeframe for preliminary technical work to 90 calendar days, keeps the list of such work closed, and prohibits the implementing organisation from expanding it, while the window for submitting applications under the national procedure takes 2027-12-31 as its key milestone, so route selection must be decided in step with the time window. Second, local authorised representative services: GRZAN can act as the statutory representative of a manufacturer in Belarus, undertaking registration submission, responses to technical queries, changes to the registration dossier and post-market reporting obligations, and it has updated its liaison mechanisms after the Council of Ministers Resolution No. 378 of 27 July 2026 (effective 2026-07-30) transferred adverse event functions to the state agency State Pharmaceutical Supervision (Gosfarmnadzor). Third, quality system and testing support: GRZAN assists in establishing a quality management system that meets ISO 13485 requirements and organises technical documentation according to the target route — for the national route, per the annexes to Ministry of Health Resolution No. 55; for the Union route, per EEC Council Decision No. 46.

For business enquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail